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Abstract
BACKGROUND & AIMS—Patients with inflammatory bowel disease (IBD) are at risk for
certain malignancies. We aimed to determine the risk of melanoma and nonmelanoma skin cancer
(NMSC) in patients with IBD and how medications affect these risks.
METHODS—We performed retrospective cohort and nested case-control studies using
administrative data from the LifeLink Health Plan Claims Database from 1997 to 2009. The
cohort comprised 108,579 patients with IBD, and each was matched to 4 individuals without IBD.
The risk of melanoma and NMSC was evaluated by incidence rate ratio (IRR) and by adjusted
Cox proportional hazard ratio (HR) modeling. In nested case-control studies, patients with
melanoma or NMSC were matched to 4 patients with IBD without melanoma or NMSC.
Conditional logistic regression was used to determine associations between medications and both
skin cancers.
RESULTS—In the cohort, IBD was associated with an increased incidence of melanoma (IRR,
1.29; 95% confidence interval [CI], 1.09–1.53). Risk was greatest among individuals with Crohn’s
disease (IRR, 1.45; 95% CI, 1.13–1.85; adjusted HR, 1.28; 95% CI, 1.00–1.64). The incidence of
NMSC also increased among patients with IBD (IRR, 1.46; 95% CI, 1.40–1.53) and was greatest
among those with CD (IRR, 1.64; 95% CI, 1.54–1.74). In the nested case-control studies, therapy
with biologics increased the risk of melanoma (odds ratio [OR], 1.88; 95% CI, 1.08–3.29).
Patients who had been treated with thiopurines had an increased risk of NMSC (OR, 1.85; 95%
CI, 1.66–2.05).
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CONCLUSIONS—Immunosuppression increases the risk of melanoma and NMSC among
patients with IBD. The risk of melanoma is increased by use of biologics, and the risk of NMSC is
increased by use of thiopurines. Patients with IBD should be counseled and monitored for skin
cancer.
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It is estimated that 68,130 Americans were diagnosed with melanoma and 8700 Americans
died of melanoma in 2010. The age-adjusted incidence rate for melanoma in the United
States from 2004 to 2008 was 20.8 cases per 100,000 men and women per year. The rate of
melanoma has nearly tripled in the white population over the past 20 years.1,2
Nonmelanoma skin cancer (NMSC) is also on the rise. From 2002 to 2006, there was a 16%
increase in procedures for NMSC. In 2006, the total number of NMSCs in the US population
was estimated to be 3,507,693.3
The risk factors for skin cancers include both environmental and genetic factors.
Epidemiologic evidence has shown an increased risk of melanoma among those with
extensive exposure to sunlight.4 Intermittent intense sun exposure in adolescence, often
associated with a sunburn, confers an increased risk of melanoma.5 Sites closer to the
equator have an increased risk,6 and a north-south gradient of melanoma has been shown in
the United States.1 In contrast, NMSC is associated with cumulative sun exposure risk,
rather than the intensity of the exposure, as is seen with melanoma. High numbers of nevi on
the body and fair complexion are also associated with increased risk of skin cancer.7
Immunosuppressive medications are another important risk factor for skin cancers. Solid-
organ transplant recipients have a 3.4-fold increased risk of melanoma8; the risk of NMSC
in this population is estimated to be even higher. For example, squamous cell skin cancer is
65–250 times more common in posttransplant populations.9 In general, the risk of skin
cancer correlates with degree of immunosuppression.8 Consequently, it is recommended that
organ transplant recipients undergo routine skin surveillance due to the increased risk of skin
cancer in this population.10 Recent data have shown an increased risk of NMSC in patients
with inflammatory bowel disease (IBD),11–13 particularly associated with the thiopurine
class of medications. Little is known about the risk of melanoma in patients with IBD and
the specific risks of various immunosuppressive medications used in the treatment of IBD,
including the biologic anti–tumor necrosis factor α (anti-TNF) medications. Case reports
and a recent meta-analysis have suggested an association between biologic anti-TNF
medications and risk of melanoma.14–16 Defining the risk of melanoma in patients with IBD
is paramount, because preventive measures (such as sunscreen use) have been shown to
reduce the incidence of melanoma.17
The specific aims of this study were (1) to quantify the risk of melanoma and NMSC among
a US cohort of patients with IBD as compared with a non-IBD cohort and (2) to evaluate the
risk of melanoma and NMSC among patients with IBD who use immunosuppressive or
biologic anti-TNF medications as compared with patients with IBD who have not used these
medications.
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We analyzed the inpatient and outpatient procedural and outpatient pharmaceutical
insurance claims contained in the LifeLink Health Plan Claims Database (IMS Health,
Norwalk, CT) for the period January 1, 1997, through December 31, 2009. The source
database contains enrollment information on more than 60 million persons from more than
98 health plans across the United States. This longitudinal, patient-level database has also
been used in previous epidemiologic studies of IBD.11,18 The specific data extract used for
this study includes data covering a long period to better study newer medications used in the
treatment of IBD. Prior studies have reported the LifeLink Health Plan Claims Database to
be representative of the commercially insured US population on a variety of demographic
measures.19
Study Design
We performed a retrospective cohort study to determine the overall risk of melanoma and
NMSC in patients with IBD compared with a non-IBD cohort. We then performed nested
case-control studies to determine the independent effects of medication use
(immunosuppressive and biologic anti-TNF therapy) on melanoma and NMSC among
patients with IBD. A similar design has previously been used by our group11 and also by
Gupta et al20 to evaluate the incidence of disorders in patients with IBD and the effects of
various medications.
Cohort Study
Patient selection—Eligibility criteria for inclusion in the cohort were at least 12 months
of continuous health plan enrollment with pharmacy benefits, no history of human
immunodeficiency virus (HIV) due to inherent immune system differences, and age younger
than 64 years. We chose 64 years as the upper age limit to avoid the possibility of missing
data resulting from Medicare dual eligibility (which begins at age 65 years). We identified
cases of Crohn’s disease (CD) and ulcerative colitis (UC) using a previously reported
administrative definition updated to include medications recently approved for IBD
indications.21 Specifically, patients with IBD were identified by either of 2 definitions: (1) a
minimum of 3 health care contacts, on different dates, associated with an International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) diagnosis code for
CD (555.xx) or UC (556.xx) or (2) at least one claim for CD or UC plus a pharmacy claim
for any of the following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-
mercaptopurine, azathioprine, methotrexate, infliximab, adalimumab, certolizumab pegol,
natalizumab, and enteral budesonide. For patients who had claims for both CD and UC,
disease assignment was made according to the majority of the last 9 claims or, if there were
fewer than 9 claims, the majority of available claims. Those with equal numbers of CD and
UC claims were categorized as unknown IBD type. For the comparison cohort, each patient
with IBD was matched to 4 non-IBD persons by age, sex, and month of enrollment (±6
months). Persons having any IBD claims (based on ICD-9) who did not meet our definition
of IBD were ineligible for the comparison cohort.
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Cohort lead time and follow-up—For the entire cohort, we required 6 months of lead
time or screening time before the start of follow-up for outcome ascertainment to minimize
possible inclusion of prevalent outcomes and to allow assessment of potentially confounding
patient characteristics at the time of entry into the cohort. Thus, for patients with IBD, we
required 6 months of enrollment before the first qualifying IBD claim; for non-IBD, we
required 6 months of enrollment before the enrollment date of the case to whom they were
matched.
Each member of the cohort was followed up until the first diagnosis of melanoma or, if
none, until censoring at the earlier of one of 2 events: discontinuation of primary or
pharmacy insurance coverage or age older than 64 years.
Assessment of melanoma outcome—The primary outcome of interest was first
diagnosis of melanoma. The standard definition included both pathologic and surgical
components, requiring 2 separate elements within 30 days: (1) a claim containing a Current
Procedural Terminology, 4th edition (CPT-4) code for interpretation of pathology from an
office or surgical setting (88301–88309) accompanied by an ICD-9 diagnosis code of
melanoma (172.0–172.9) on the same line AND (2) within 30 days, a claim containing a
CPT-4 code for excision of malignant lesions (11600–11646) or a CPT-4 code for Mohs
stage 1 excision (17311 or 17313).
To assess the adequacy of our primary definition, we also specified 2 alternate definitions,
one more sensitive and one more specific. The more sensitive definition was any single
ICD-9 code for melanoma (172.0–172.9). This definition has been validated within
Medicare administrative data via linkage to the Surveillance, Epidemiology, and End Result
(SEER) tumor registry and has been found to have a sensitivity of 90.1%.22 The more
specific definition required all 3 diagnostic, pathologic, and surgical components (CPT-4
code for pathology AND ICD-9 for melanoma AND CPT-4 for surgery or excision) on the
same date. These alternate definitions were used to perform sensitivity analyses of our
primary definition of melanoma. Persons with any melanoma claim (ICD-9 172.0–172.9)
during the 6-month lead or screening period (before start of follow-up) were excluded to
minimize possible inclusion of prevalent cases.
Assessment of NMSC outcome—The definition of NMSC was based on a definition
we used in prior work, updated to account for changes in procedure codes for Mohs excision
that went into effect in 2007.11 The NMSC definition consisted of (1) a claim containing a
CPT-4 code for interpretation of pathology from an office or surgical setting (88301–88309
and/or 88329–88332) and an ICD-9 diagnosis code of NMSC (173.0–173.9 or 232.0–232.9)
or (2) a claim containing a CPT-4 code for destruction or excision (116xx, 172xx, 17300–
17315) and one of the previously mentioned ICD-9 codes of NMSC.
Assessment of exposures—Patient exposures and potentially confounding
characteristics were assessed using claims from the 6-month lead or screening period before
start of follow-up in 3 domains: utilization, comorbidity, and medication use. Health care
utilization was defined as the total number of discrete days with at least one
nonpharmacologic health care contact over the screening period. Utilization has been
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measured in this fashion in prior pharmacoepidemiology studies of IBD in this data set.23 To
identify comorbidities, we used the enhanced version of the validated Charlson–Deyo
comorbidity index for administrative data developed by Quan et al.24,25 This is a score
composed of weighted values of 17 selected comorbidities, where higher scores are
associated with greater burden of comorbid disease. We excluded malignancy from the list
of comorbidities for the melanoma outcome, because melanoma itself is an included
malignancy. Use of immunosuppressive or biologic anti-TNF medication use was
dichotomized as any use versus none for each of the following medications: 6-
mercaptopurine, azathioprine, methotrexate, tacrolimus, cyclosporine, mycophenolate
mofetil, infliximab, adalimumab, certolizumab pegol, or natalizumab. Any use was defined
as one or more claims for a given medication. We also assessed use of 5-aminosalicylic acid
(5-ASA) medications (sulfasalazine, balsalazide, mesalamine, olsalazine) in the same any/
none fashion.
Statistical analysis—We used descriptive statistics to summarize characteristics of
patients with and without IBD. Continuous variables are reported as mean ± SD or median
with interquartile range, and categorical variables are reported as percentages. We calculated
incidence rates of melanoma and NMSC (per 100,000 person-years) and incidence rate
ratios (IRRs) comparing the incidence of melanoma and NMSC in IBD and non-IBD
patients. To control for confounding, we first assessed possible violation of the proportional
hazards assumption via log-log plots and testing of Schoenfeld residuals. Because the
assumption was not violated, we used Cox proportional hazard models to calculate hazard
ratios (HRs) and 95% confidence intervals (CIs) for the risk of melanoma and NMSC in the
IBD cohort as compared with the non-IBD cohort, controlling for health care utilization and
comorbidities. In stratified analyses of CD and UC, the control group was limited to the
respective matched non-CD and matched non-UC subjects.
Nested Case-Control Study
We next conducted a case-control study evaluating the association between
immunosuppressive or biologic anti-TNF medication use and melanoma. This study was
nested within the previously defined cohort of patients with IBD. An identical method was
used to assess associations between medication use and the NMSC outcome.
Selection of cases and controls—For each case-control study, cases were patients
with IBD who were diagnosed with melanoma or NMSC, respectively, and controls were
patients with IBD who were disease-free (melanoma or NMSC) at the time of selection.
Each case patient was matched to up to 4 IBD patient controls on sex, age (within 2 years),
region of the country, disease type (CD or UC), and month of the case’s diagnosis incidence
density sampling. In this sampling technique, potential controls for a given case need only
be diseasefree up to the index date, which is the diagnosis date of the case being matched. A
control may become a case subsequent to this date, and once a person is diagnosed (becomes
a case), he or she is no longer eligible to serve as a control. The index date for each matched
set is the date of diagnosis of the case; all exposures were assessed retrospectively from this
date.
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Medication use: The primary medications evaluated included azathioprine and 6-
mercaptopurine (thiopurine class), methotrexate, tacrolimus and cyclosporine (calcineurin
class), mycophenolate mofetil, infliximab, adalimumab, certolizumab pegol (biologic anti-
TNF class), and natalizumab. We also assessed any 5-ASA medication use (sulfasalazine,
balsalazide, mesalamine, olsalazine). All medication use preceding the diagnosis of
melanoma or NMSC in cases or preceding the matching index date in controls was analyzed
in an any/none fashion.
Other: Health care utilization and comorbidities were determined in the same manner as in
the cohort except the referent period for these exposures was the period between 4 and 9
months before the index date for each matched set. The offset of 4 months before diagnosis
was chosen so that increased utilization or comorbidities associated with the diagnosis of
melanoma or NMSC would not be included in the exposure assessments. As in the cohort,
utilization was defined as the number of distinct nonpharmaceutical claim dates in the
reference period, and comorbidities were assessed using the Quan update of the Deyo
comorbidity index for administrative claims data, excluding malignancies.24,25
Statistical analysis—Characteristics of cases and controls were summarized using
descriptive statistics. Bivariate analyses were used to compare medication use within cases
and controls. We used conditional logistic regression to calculate crude and adjusted odds
ratios (ORs) and 95% CIs for each medication exposure and case status. We controlled for
potential confounders, including other medication use, health care utilization, and




The cohort study population included 108,579 patients with IBD. Of these, 50,920 had CD,
56,390 had UC, and 1269 had IBD with unknown type. There were a total of 434,233
individuals in the non-IBD comparison cohort. The median length of follow-up within this
cohort was 24 months (interquartile range, 12–43), with a range from 1 to 138 months.
Length of follow-up was similar for CD (35 months; interquartile range, 21–52) and UC
populations (37 months; interquartile range, 22–57) while significantly less in the non-IBD
comparison cohort (21 months; interquartile range, 10–39; P < .01). Characteristics of the
patients with IBD as compared with the non-IBD cohort are shown in Table 1.
Characteristics in general were well matched, with increased health care utilization and
immunosuppressive medication use among the patients with IBD and among the patients
with CD as compared with patients with UC.
Melanoma—For patients with IBD, the overall annual incidence of melanoma was
57.1/100,000, compared with 44.1/100,000 in the non-IBD cohort (Figure 1). When
melanoma was evaluated within 10-year age strata, incidence increased with advancing age
for both the IBD and non-IBD cohort. Patients with IBD had an increased risk of melanoma
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(IRR, 1.29; 95% CI, 1.09–1.53). There were differential findings by disease subtype, with
significantly increased risk for CD (IRR, 1.45; 95% CI, 1.13–1.85) but not for UC (IRR,
1.13; 95% CI, 0.89–1.42).
When using Cox proportional hazards modeling to adjust for health care utilization and
comorbidities, the risk was not significantly elevated in the overall IBD population as
compared with the non-IBD population (adjusted HR, 1.15; 95% CI, 0.97–1.36). Again,
there were differential effects by subtype, with increased risk for CD (adjusted HR, 1.28;
95% CI, 1.00–1.64) and not for UC (adjusted HR, 1.02; 95% CI, 0.81–1.29). In analyses
using the 2 alternate definitions of the melanoma outcome, one with increased sensitivity
and one with increased specificity, the overall IRRs for the IBD population as compared
with the non-IBD population were similar (IRR, 1.20 [95% CI, 0.99–1.44] and IRR, 1.28
[95% CI, 1.16–1.41], respectively). Table 2 shows the sensitivity analyses (base case, more
sensitive, more specific) stratified by disease subtype.
To investigate whether the relative risk of melanoma among patients with IBD is increasing
over time, we assessed IRRs in 3 subcohorts defined by date of enrollment in 3 distinct
periods (1997–2000, 2001–2004, 2005–2009). In effect, these were 3 separate closed
cohorts. In these exploratory analyses, we did find a trend for increasing risk of melanoma
with time (IRR of 1.1, 1.3, and 1.5, respectively), providing indirect support for hypotheses
that increasing use of immunosuppressive medications may play a causative role.
Interestingly, when we also investigated medication use over these periods, biologic anti-
TNF use dramatically increased. From 1997 to 2000, there were 69 prescriptions of biologic
anti-TNF medications per 100,000 person-months. This increased to 2826 per 100,000
person-months from 2005 to 2009. Annual increase in biologic anti-TNF use is shown in
Supplementary Figure 1.
NMSC—Patients with IBD had an overall incidence of 912/100,000 for NMSC, as
compared with 623/100,000 in the non-IBD comparison cohort. Patients with IBD had an
increased risk of NMSC (IRR, 1.46; 95% CI, 1.40–1.53), as did both CD (IRR, 1.64; 95%
CI, 1.54–1.74) and UC (IRR, 1.34; 95% CI, 1.26–1.42) subtypes. Similar results were found
in analyses adjusted for comorbidities and health care utilization, with an increased risk in
the IBD population overall (adjusted HR, 1.34; 95% CI, 1.28–1.40) and for CD (adjusted
HR, 1.48; 95% CI, 1.39–1.58) and UC (adjusted HR, 1.23; 95% CI, 1.16–1.31).
Nested Case-Control Study
Melanoma—The study population for the nested case-control study of melanoma in
patients with IBD included 209 cases of melanoma and 823 matched controls (2 cases of
melanoma could not be matched, and a few cases had <4 matches). Health care utilization,
exposure to any biologic anti-TNF medication, and any 5-ASA medication were all higher
among cases than controls (Table 3). Differences in any use of 5-ASA, thiopurine, and
biologic anti-TNF medication use are shown in Table 4. In the overall study population and
in the CD stratum, cases had significantly greater biologic anti-TNF medication use when
compared with controls.
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Adjusted multivariate analyses are shown in Table 5. In the overall IBD population, use of
any biologic anti-TNF medication was associated with melanoma in crude (OR, 2.08; 95%
CI, 1.24–3.51) and adjusted analyses (OR, 1.88; 95% CI, 1.08–3.29). There was no
significant association with any thiopurine or any 5-ASA use. We performed 2 exploratory
subanalyses in an attempt to evaluate whether the risk associated with anti-TNF biologics
was associated with length of exposure. In the subset of persons with 1 or more years of
enrollment before melanoma (or control index date), there was no risk associated with anti-
TNF biologic exposure less than 120 days’ duration (crude OR, 0.97; 95% CI, 0.19–4.98).
In a second subanalysis, we defined a surrogate marker for long-term use based on current
use of anti-TNF biologics at the time of entry into cohort follow-up versus patients who
were not using these drugs at enrollment. The adjusted OR for this indicator (long-term vs
non–long-term use) was 3.93 (95% CI, 1.82–8.50).
NMSC—The nested case-control study of patients with IBD who had NMSC included 3288
cases of NMSC and 12,945 controls. Similar to the melanoma case-control study, health
care utilization and immunosuppressive medication use (anti-TNF biologic and thiopurine)
were higher among cases of NMSC (data not shown). Any thiopurine use was associated
with an increased risk of NMSC in crude (OR, 1.98; 95% CI, 1.79–2.20) and adjusted
analyses (adjusted OR, 1.85; 95% CI, 1.66–2.05). However, anti-TNF biologics were not
associated with significantly increased risk in adjusted analyses (OR, 1.14; 95% CI, 0.95–
1.36). Summary medication effects are shown in Table 5. As with our prior study of NMSC
in IBD, we also assessed NMSC risk by medication duration. We investigated both recent (3
months) and persistent use (≥1 year). We found increasing risk associated with increasing
duration of both anti-TNF biologic and thiopurine medications (data not shown). In a
subanalysis, combined use of thiopurines and biologics for ≥1 year was associated with the
greatest increased NMSC risk (adjusted OR, 3.89; 95% CI, 2.33–6.46), followed by
persistent thiopurine use alone and biologic anti-TNF use alone as compared with no use of
these medications (Supplementary Table 1).
Discussion
Over the past 2 decades, there have been important advances in the therapy of IBD,
including the addition of efficacious medications such as thiopurines and biologic anti-TNF
agents to the therapeutic armamentarium. These medications have allowed for dramatic
improvements in maintenance of clinical remission, endoscopic remission, and quality of
life for patients with IBD. As these medications are used in increasing numbers for
individuals with IBD, it becomes important to understand complications that may be
associated with these medications, such as malignancy. Some malignancies in patients with
IBD, such as skin cancer, are potentially preventable with modification of concomitant risk
factors.
The risks of lymphoma,26 and more recently NMSC,11–13 associated with thiopurine use
have been well described. Less is known about the risks of other malignancies, such as
melanoma, and the risks of biologic anti-TNF medications.
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Other immunosuppressed populations, such as organ transplant recipients, have a markedly
increased risk of NMSC and, to a lesser extent, increased risk of melanoma. In Europe and
Australia, the risk of melanoma has been reported to be 1.6-fold to 4-fold higher in
transplant recipients when compared with the general population,9 where the mean interval
between transplantation and diagnosis of melanoma was 5 years. Melanoma accounts for
6.2% of posttransplantation skin cancers in adults and 15% in children.9
In our study, we found an increased risk of melanoma in patients with CD (adjusted HR,
1.28; 95% CI, 1.00–1.64). The increased risk may be related to a combination of factors,
including the immune dysfunction associated with IBD, the medications used in the therapy
of IBD, or increased detection of melanoma in this population related to residual
confounding from IBD-associated increased health care utilization. We found an incidence
of melanoma in patients with IBD of 57.1/100,000, with a further increased incidence
among patients with CD of 60.8/100,000. A prior study of melanoma risk in the US
rheumatology population, where similar immune dysfunction and medication therapies exist,
found a markedly similar incidence of melanoma of 65.6/100,000.27 In other population-
based studies of malignancy in IBD, including a recent meta-analysis, the risk of melanoma
has not been found to be increased.23–31 We speculate that this may be related to the large
sample size needed to detect a difference in a rare outcome such as melanoma and because
many of these studies were conducted in an era before widespread use of
immunosuppressive medications and biologic anti-TNF medications. Indeed, in a
subanalysis of time trends, we found that the risk of melanoma in the IBD cohort, relative to
the comparison cohort, increased from 1.1 between 1997 and 2000 to 1.5 between 2005 and
2009. Over this same period, prescriptions for anti-TNF biologic agents also dramatically
increased. This provides ecological support for the hypothesis that increasing use of anti-
TNF agents may be associated with increasing risk of melanoma.
Our nested case-control study results also show an association between medication use and
melanoma in patients with IBD. Specifically, we found an increased risk of melanoma with
biologic anti-TNF use. An increased risk of melanoma associated with biologic anti-TNF
use has also been reported in an observational study of the US rheumatology population
(OR, 2.3; 95% CI, 0.9–5.4). Drug-specific risks in this group showed that infliximab was
associated with melanoma (OR, 2.6; 95% CI, 1.0–6.7).27 A similar magnitude of increased
risk has been found in a recent meta-analysis of cancer risk in patients with rheumatoid
arthritis treated with biologic anti-TNF medications (pooled risk estimate for melanoma,
1.79; 95% CI, 0.92–2.67).32 The mechanism behind this increased risk is not known. It is
possible that melanoma occurs after biologic anti-TNF therapy due to unleashing of a
previously checked melanoma by the immune system. Alternately, a melanoma could
develop de novo after a biologic anti-TNF medication is initiated due to increased
photosensitivity or other alternate mechanism. In our study of NMSC, although there was no
increased risk with “any” biologic anti-TNF use, we did find increasing risk with increasing
duration of use. The risk of NMSC with ≥ 1 year of biologic anti-TNF therapy was
significantly increased (adjusted OR, 1.58; 95% CI, 1.16–2.14), similar to our prior work.
We did not find a significant association with any use of thiopurines and melanoma, but this
risk did trend upward in the UC population. We found a significantly greater risk of NMSC
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in patients with IBD with any thiopurine use (OR, 1.85; 95% CI, 1.66–2.05), as has been
noted previously.11–13 The mechanism of increased NMSC risk is believed to be related to
selective photosensitivity to UVA light via 6-thioguanine DNA photoproducts.33,34 Because
thiopurines do not alter the risk of melanoma to the same extent, a different mechanism of
increased risk of melanoma is likely. It is interesting that the OR for melanoma associated
with any 5-ASA use was also elevated for patients with UC, although not significantly so.
Although photosensitivity has been reported as a side effect of 5-ASA medications,
particularly sulfasalazine,35 these are not immunosuppressive medications and have not
previously been associated with risk of skin cancer. Additionally, in our study of NMSC, 5-
ASA medications were not associated with increased risk. Also, medications such as 5-ASA,
thiopurines, or biologics may be markers of increased disease activity, which may correlate
with an increased level of immune dysfunction from the underlying IBD and/or increased
opportunities for detection due to more regular health care contact.
There are several strengths to this study. Most importantly, the study population was very
large (source population of approximately 60 million individuals), which is essential in a
study of rare outcomes such as melanoma. We also had broad geographic diversity, with
patients included in the study from all regions of the United States. By matching individuals
on health plan region, we were able to select controls from similar latitudes in the United
States to partially account for ambient sun exposure. By drawing from a large number of
health plans of varying size, type, and location, we believe our results to be broadly
generalizable to the commercially insured US population. We obtained complete data on all
billed prescriptions to completely capture medication exposures, rather than relying on
patient recall or clinical charts where prescriptions may have been written but not filled. We
were also able to account for health care utilization, because we had access to all health care
contacts in the database. Finally, we were able to assess the risk of NMSC in this population,
which was shown to be elevated to a similar extent in prior work.11 This allows for a
comprehensive review of skin cancer risk in IBD and puts the risk of melanoma in
perspective, because the absolute risk of NMSC is much higher.
There are also several limitations to this study. Because this is a study using administrative
claims data, there is the possibility of misclassification of exposure and outcome related to
the lack of clinical detail. To minimize this risk, we used an IBD exposure definition
previously used by our group11,18 that requires multiple health contacts and/or IBD-related
prescriptions. A similar but less specific administrative case definition has been validated by
Herrinton et al and was found to have a sensitivity exceeding 90% and a positive predictive
value exceeding 80% for overall IBD.36 We used an outcome definition of melanoma
consisting of multiple contacts, with pathology and excision coding combined with an
ICD-9 code for melanoma. We were unable to validate this outcome within our deidentified
data. However, in a validation study linking claims data with population-based cancer
registry data in a rheumatoid arthritis population, a cancer definition based on diagnosis
codes plus cancer-related procedure codes (such as our definition) had a specificity of 99%
and a sensitivity of 80% for most types of cancer.37 Our definition of NMSC has been used
in prior work11 and similarly consists of diagnosis and procedure-related codes.
Nonetheless, there may be a measurement error associated with outcome measurement, but
because this should be nondifferential in the IBD and non-IBD cohorts, it would bias our
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effect estimate toward the null. We additionally used alternate definitions of melanoma in
sensitivity analyses and found similar relative risk results with both a more specific and a
more sensitive definition. Further support for the validity of the administrative definition of
melanoma used in this study is that the incidence in both the IBD and comparison cohorts
increased with age, consistent with prior literature.
Another limitation to this study is that the elderly and uninsured were not represented in our
population. To the extent that melanoma increases with age, we were unable to address
whether the risks may differ in the elderly. In the general population, the incidence of
melanoma gradually increases with age for both men and women, with a peak incidence of 1
in 52 for men and 1 in 123 for women aged 70 years and older; comparatively, these figures
are 1 in 158 and 1 in 180 for men and women aged 40–59 years, respectively.38 However,
the lack of older persons in our study population does not affect the validity of the relative
risk measures (IRRs, HRs, ORs) we presented in the context of the population younger than
65 years. Additionally, because of small numbers of melanoma outcomes and medication
exposures in the cohort, we were unable to assess the risk of melanoma with combined anti-
TNF and thiopurine therapy. We were able to assess this risk for the much more common
NMSC and found that combined anti-TNF and thiopurine therapy was associated with the
highest relative risk (adjusted OR, 3.89; 95% CI, 2.33–6.46).
A final set of limitations involves the inability to account for exposures not captured in the
claims database, including medication use before health plan enrollment, smoking status,
socioeconomic status, and race/ethnicity. We were able to obtain data on chronic obstructive
pulmonary disease, which has been used as a proxy for smoking status in other studies using
administrative data, and this was not significantly associated with the outcome of melanoma.
Race could be an unmeasured confounder if it is associated with both the outcome and the
exposure. White race is associated with increased risk of melanoma and NMSC. Race may
also be associated with IBD and with immunosuppressive medication use. However, several
studies suggest that the incidence of IBD among black subjects is approaching that of white
subjects. Because our nested case-control study investigated only the IBD population, race
would not have been a confounder unless associated with the medication exposures. Among
studies that have shown differences in immunosuppressive medication use by race, many
cite access to care and socioeconomic factors as a potential cause.39 Patients with IBD are
known to have higher socioeconomic status,40 and this also could be associated with the
outcome of melanoma.41 However, in our study, all patients are insured and have access to
care, thereby minimizing the potential for confounding by socioeconomic factors.
Additionally, we did control for health care utilization within our study, a proxy for access
to care.
In summary, we found that increased risk of melanoma in patients with IBD is driven by use
of anti-TNF biologics, whereas increased risk of NMSC is driven by use of thiopurines.
Although we found an association between biologic anti-TNF use and melanoma, the
absolute risk of melanoma in patients with IBD remains quite low at 57/100,000 person-
years. By comparison, the absolute risk of NMSC was much greater at 912/100,000 person-
years. The mildly increased relative risk of melanoma with biologic anti-TNF medications
likely does not outweigh the benefits in patients with moderate to severe IBD and should not
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deter use of these efficacious medications, and neither should the increased relative risk of
NMSC with thiopurines. Instead, providers should emphasize the importance of skin cancer
prevention in those who require these medications. Options for primary prevention of both
melanoma and NSMC include sun avoidance, sun protection via sunscreen, or use of sun-
protective clothing.42 In fact, a recent randomized controlled trial of sunscreen use in the
general population in Australia found that sunscreen reduced the incidence of melanoma.17
This has long been known to be true for NMSC. Another consideration for at-risk
populations, such as those with IBD, is application of secondary preventive measures such
as routine skin screening examinations. This may be particularly important in the IBD
population using immunosuppressive medications and warrants further study.
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Incidence of melanoma in IBD and non-IBD populations. Data from IMS Health, LifeLink
Health Plan Claims Database, from 1997 to 2009.
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Table 2












  Base casea 1.29 (1.09–1.53) 1.45 (1.13–1.85) 1.13 (0.89–1.42)
  More sensitiveb 1.28 (1.16–1.41) 1.31 (1.14–1.52) 1.24 (1.08–1.41)
  More specificc 1.20 (0.99–1.44) 1.30 (0.98–1.73) 1.10 (0.85–1.41)
NOTE. Matched characteristics include age (within 2 years), sex, region of the country, and IBD subtype. Data from IMS Health, LifeLink Health
Plan Claims Database, from 1997 to 2009.
a
Main outcome, a claim containing (1) a CPT-4 code for interpretation of pathology from an office or surgical setting (88301–88309) accompanied
by an ICD-9 diagnosis code of melanoma (172.0–172.9) on the same line AND (2) within 30 days, a claim containing a CPT-4 code for excision of
malignant lesions (11600–11646) or a CPT-4 code for Mohs stage 1 excision (17311 or 17313).
b
Any one ICD-9 diagnosis code of melanoma (172.0–172.9).
c
All 3 diagnostic, pathologic, and surgical components (CPT-4 code for pathology AND ICD-9 for melanoma AND CPT-4 for surgery or excision)
on the same date.
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Table 3
Characteristics of the IBD Population by Melanoma
No melanoma (n = 823) Melanoma (n = 209)
Characteristicsa n % or median (IQR) n % or median (IQR) P valueb
Age (y)c 823 50 (41–56) 209 50 (42–56) .52
Sex (% female) 436 53.0 110 52.6 .93
IBD type
  CD 402 48.9 102 48.8 .47
  UC 416 50.6 104 49.8
  Unknown 5 0.6 3 1.44
Utilizationd 823 2 (0–5) 209 4 (1–7) <.01
Region
  East 140 17.0 36 17.2 .99
  Midwest 368 44.7 92 44.0
  South 149 18.1 39 18.7
  West 166 20.2 42 20.1
Comorbidities
  Cardiac 10 1.2 4 1.9 .44
  Diabetes mellitus 51 6.2 8 3.8 .19
  Liver disease 10 1.2 3 1.4 .80
  Renal 3 0.4 3 1.4 .07
  Chronic obstructive pulmonary disease 36 4.4 12 5.7 .40
No. of comorbiditiese 823 0 (0–0) 209 0 (0–0) .71
NOTE. Data from IMS Health, LifeLink Health Plan Claims Database, from 1997 to 2009.
a
Matched factors include age (within 2 years), sex, health plan region, and IBD subtype.
b
P value by Pearson χ2 test for categorical variables and Wilcoxon rank sum test for continuous variables.
c
Age at time of melanoma (case) or index date (control).
d
Defined as total number of days (continuous) with any health care contact over a 6-month period.
e
Number of comorbidities from Charlson comorbidity index, excluding malignancy.
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